63 results about "Viral structural protein" patented technology

The present invention describes recombinant adenoviral vectors modified by incorporating targeting ligands or label into viral capsid or structural proteins. In one embodiment, single-chain antibody was introduced into the minor capsid proteins pIIIa or pIX so that the adenoviral vector can be targeted to a particular cell type. In another embodiment, there is provided a noninvasive imaging strategy useful for monitoring the replication and spread of conditionally replicative adenoviral vectors. Viral structural proteins such as pIX capsid protein, core proteins mu, V and VII were expressed as fusion protein with a fluorescent label. Once incorporated into the virions, detection of the structural fusion protein label would indicate the localization of the disseminated viral progeny. The detected fluorescent signals also closely correlate with the level of viral replication and progeny production.

The present invention provides a virus like particle comprising a virus structural protein and an antigen derived from PD-1 or a ligand of PD-1, and a composition or kit comprising thereof, its use in immune response etc.

The invention discloses a monoclonal antibody 64360-52D1 capable of specifically combining with SARS-Cov-2 virus structural nucleocapsid protein (N protein), a preparation method thereof, and 6 complementarity-determining regions (CDR) of heavy chain and light chain variable regions; and more specifically, the monoclonal antibody is secreted by a hybridoma strain 64360#52D1, and can specifically recognize the SARS-Cov-2 virus N protein rather than SARS virus N protein. Thus, the monoclonal antibody can be used for identifying the two coronaviruses with high similarity. The invention further provides an enzyme-linked immunosorbent assay (ELISA) and an immune colloidal gold test strip detection method for specifically detecting the SARS-Cov-2 virus N protein by preparing the 64360#52D1 antibody. The antigen of the antibody is SARS-Cov-2 virus N protein subjected to heat treatment and expressed in mammalian cells; the finally obtained antibody belongs to an IgG1 subtype; and a sequence for encoding the variable region of the antibody is obtained in a gene cloning mode.

Fusion proteins of recombinant SARS coronavirus structural proteins, their production and uses are provided. An optimized SARS coronavirus S protein gene which can be highly expressed in the mammalian cell strains and SARS coronavirus S protein variants comprising deletion, modification or mutation amino acids 318-510 corresponding to SARS coronavirus S protein are also provided.

The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles of the invention, and methods of prevention or treatment using such compositions.

The invention discloses a hepatitis E virus-like particle vaccine preparation method, and belongs to the biological medicine technical field. According to the method, hepatitis E virus truncated capsid protein gene codon optimization is performed, prokaryotic expression system escherichia coli strain B834-pRARE2 is used, by fusion of purification tag MBP expression, different cracking agent screening and combination, bacterial membrane extraction, maltose amylose affinity chromatography, molecular sieve chromatography for removal of MBP and non-virus structural protein, and promotion of virus-like particle assembly, the hepatitis E virus-like particle purity is more than 99.0%, and is free of protein label and bioactive (in the form of non-inclusion body, and soluble). The hepatitis E virus-like particle vaccine produces complete protection to pig, dog and chicken HEV infection, cross protective antigens are between different genotype HEV virus, and the hepatitis E virus-like particle vaccine can be used as an animal vaccine to prevent the diseases and infection caused by pig, dog and poultry HEV.

The disclosure provides immunogenic compositions comprising human picornavirus peptides derived from structural proteins of the virus, constructs comprising the peptides, the peptides themselves and their use in the prevention of picornavirus infection and disease. Particular peptides from VP4 and VP1 are disclosed.

The present invention provides an isolated RNA molecule comprising: a) an alphavirus 5' replication recognition sequence, wherein at least one initiation codon has been removed from the 5' replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3' replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5' and 3' replication recognition sequences of (a) and (c) direct replication of the RNA molecule in the presence of alphavirus nonstructural proteins.

The present invention relates to recombinant coronavirus and application thereof to preparation of vaccines. A genome of the recombinant coronavirus has deficiency in a gene encoding structural protein, which results in that the recombinant virus produced solely from the genome of the recombinant virus lacks the structural protein. The invention also relates to a preparation method of the recombinant coronavirus. The preparation method comprises the following steps of (1) carrying out in-vitro amplification on virus genome segments and carrying out in-vitro splicing; (2) performing in-vitro transcription to prepare genomic RNA of the recombinant virus, wherein the genomic RNA has a mutation in the gene encoding the structural protein, which results in that the recombinant virus produced solely from the genome of the recombinant virus lacks the structural protein; (3) preparing a packaging cell line, wherein the packaging cell line stably expresses the structural protein which is lacked by the recombinant virus; and (4) transfecting the genome RNA of the recombinant virus into the packaging cell line to generate the recombinant virus. The invention also relates to the packaging cell line for preparing the recombinant coronavirus.

The invention discloses a construction method of a novel coronavirus Raman spectrum data center. The method comprises the following steps: S1, constructing a novel coronavirus structural protein Ramanspectrum database; S2, constructing a novel coronavirus nucleic acid Raman spectrum database; S3, constructing a novel coronavirus particle Raman spectrum database; S4, constructing a Raman spectrumdatabase of a novel coronavirus clinical detection sample; and storing each novel coronavirus Raman spectrum database into a novel coronavirus Raman spectrum detection server to form a novel coronavirus Raman spectrum data center. According to the invention, a set of complete novel coronavirus Raman spectrum database is effectively established, reliable standard data support is provided for the novel coronavirus Raman detection technology, and the accuracy and confidence of a detection result are effectively improved.

The invention discloses a replication-defective A virus expression vector system and a vaccine preparation method. The vector system consists of a replication-defective A virus vector of a deleted structural gene and minus strand complementary plasmids or cells containing a controllable virus A structural gene. In the preparation method, an exogenous gene target is introduced by constructing the replication-defective A virus vector of a deleted virus structural protein; and the replication-recombinant A virus can be continuously produced in a large scale by combining the minus strand complementary plasmids or cells containing the controllable A virus structural gene, so that the problem of low virus yield of a conventional A virus system can be solved, a target of preparing recombinant virus in a large scale is realized, and exogenous protein and virus sample particles can be expressed in scale. The replication-defective A virus expression vector system disclosed by the invention is suitable for large-scale production of DNA (deoxyribonucleic acid) vaccine, vector virus vaccine and exogenous protein expression.

This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the production of both DNA and protein vaccines. Therefore, the invention provides proteins and DNAs, as well as vaccines comprising the proteins and DNAs, including cellular vaccines and vectors. Other embodiments of the invention relate to methods of enhancing immune response and vaccinating against CMV, including gene therapy methods and vectors.

The invention discloses a preparing method of restructuring protein with ocean double RNA virus MABV structural protein gene, which is characterized by the following: the restructuring protein includes VP2 fusing protein or VP3 fusing protein and VP2 or VP3 protein; the VP2 fusing protein coded sequence possesses SEQ ID NO.1 nucleic acid sequence in sequence table; the VP3 fusing protein coded sequence possesses SEQ ID NO.2 nucleic acid sequence in sequence table; the polyclonal antibody produced by reconstructing protein increases confidence level during testing ocean double RNA virus MABV; it uses ELISA and western blot to test and is simpler than other method (RT-PCR, original position and so on). To set VP2 and VP3 as vaccine is safer than attenuated vaccine.

The present invention relates to foreign peptide sequences fused to recombinant plant viral structural proteins and a method of their production. Fusion proteins are economically synthesized in plants at high levels by biologically contained tobamoviruses. The fusion proteins of the invention have are useful as antigens for inducing the production of antibodies having desired binding properties, e.g., protective antibodies, or for use as vaccine antigens for the induction of protective immunity against the parvovirus. Feline parvovirus epitopes were fused to the N-terminus of the TMV coat protein, expressed in Nicotiana plants, extracted, purified, characterized and administered to animals, resulting in protective immunity.

The invention relates to a chimeric broad-spectrum oncolytic adenovirus for multi-mechanism synergistic immunotherapy and an application thereof in tumor treatment. The oncolytic adenovirus has the characteristics of triple tumor targeting regulation mechanism, modification of three virus structure genes, chimeric combination of three serum type adenoviruses and loading of three types of anti-cancer immune genes, and can activate the inherent anti-cancer activity of various virus structure proteins; the tumor cell infection capability is improved while the situation that viruses escape from interception of pre-stored neutralizing antibodies of organisms and adhesion and uptake of hepatocytes can be guaranteed; and the effect of killing cancer cells is improved and enhanced through three types of anticancer immunomodulatory genes. According to the key technology, the design concept of mutual cooperation of multiple mechanisms is ingeniously preset in a genome, the immunosuppression barrier of a tumor microenvironment can be broken, and an obvious synergistic effect is achieved on immune checkpoint inhibitor treatment and immune cell treatment. The oncolytic adenovirus disclosed by the invention belongs to a brand new type of oncolytic adenovirus, realizes real multi-mechanism synergistic interaction, is good in targeting property and strong in anticancer activity, has broad spectrum, and can be independently or auxiliarily used for treating cancers, especially solid tumors.